Articles tagged with Cancer Medication
Researchers at UCLA have identified a molecular signature that can predict which patients with glioblastoma, a deadly brain cancer, are likely to respond to drug therapy. The discovery involves the presence of a mutant protein and a tumor suppressor protein called PTEN.
PET imaging with FDG is a powerful tool in determining the extent of spread of reproductive system cancers, particularly when other conventional tests are ambiguous. Studies have shown its high sensitivity in detecting nodal disease in cervical cancer and its superior detection abilities compared to CT or MRI in recurrent ovarian cancer.
Researchers found that people with Barrett's esophagus who regularly took NSAIDs like aspirin had a one-third reduced risk of esophageal adenocarcinoma. The protective effect wears off quickly, and the risk reverts back to never users after three years of discontinuing use.
Researchers found that drugs inhibiting MEK selectively inhibit growth of cancer cells with BRAF and RAS mutations, leading to clinical trials for patients with melanoma, colon, breast, and lung cancers. The study identifies a novel class of targeted therapies, which may be more effective and less toxic than traditional chemotherapies.
A study of 304 recently diagnosed cancer patients found that 57% of pre-diagnosis CAM users continued to use it after diagnosis, with post-diagnosis use being almost universally helpful. The study highlights the importance of addressing psychosocial needs and communication barriers in cancer care.
A new drug developed at UC Davis in collaboration with Finnish researchers shows promise in preventing breast cancer and treating post-menopausal vaginal atrophy. The study found that the drug inhibited breast cancer development by 95% in mice, suggesting a potential benefit for millions of women.
Lung cancer researchers are exploring new approaches to prevent and treat the disease, including nicotine vaccines that can reduce tobacco dependence. Additionally, studies on chemoprevention strategies aim to identify populations at high risk for lung cancer and design effective prevention methods.
Researchers have identified compounds that can reduce cancer incidence, including thiazolidinediones for type-2 diabetes patients. Synthetic triterpenoids like CDDO-Im also show potent protection against liver tumors.
Researchers have unveiled a new technique to characterize binding interactions of multivalent molecules designed for targeted drug delivery in cancer treatment. This method, using atomic force microscopy, shows promise for optimizing binding affinity and designing better antibodies.
Researchers developed nanoparticles that can target and deliver drugs to prostate cancer cells using aptamers, achieving highly specific and efficient tumour targeting. The bioconjugates successfully adhered to PSMA-positive prostate cancer cells and were rapidly internalised into the targeted cells.
A survey of 1,139 smoking patients found that women are more likely than men to believe nicotine causes cancer and feel guilty about their smoking habit. Women also reported a higher fear of gaining weight and managing stress without cigarettes when quitting, highlighting the need for targeted tobacco cessation programs.
Researchers at Johns Hopkins Kimmel Cancer Center have found hormone therapy will not diminish the value of radiation for prostate cancer. Additionally, a leukemia drug shows modest benefits in suppressing PSA levels for some men with localized prostate cancer.
Dr. Lippman's work has uncovered new means of treating and preventing several types of cancer through his research on molecular biology and carcinogenesis. His studies have also led to the development of molecular targeted drugs for cancer prevention, including trials for high-risk populations.
The Lance Armstrong Foundation has established an endowed chair in oncology at Indiana University, providing $1.5 million for research and program development. Dr. Einhorn, a renowned expert on urologic cancer, will lead the initiative to improve patient therapies and quality of life.
A study found that relatives of women with bilateral breast cancer and a normal CHEK2 gene are at a 23.8% risk by age 80, while those with the faulty variant have a 58.8% risk. Testing for the CHEK2*1100delC mutation in women with family history could be useful for predicting personal risks.
Researchers analyzed data from 79,994 women to evaluate associations of statins, lipid-lowering drugs, and serum cholesterol levels with breast cancer. No link was found between these factors and breast cancer risk.
Researchers analyzed medication orders from outpatient clinics and found a three percent overall error rate and two percent serious error rate. Most errors were due to omitted dosages or incorrect orders, but serious harm was avoided by existing checks in most cases.
Researchers found that 3% of medication orders contained errors, with 60% of pediatric errors and 82% of adult errors having potential to harm patients. Hospitals implemented changes to their automated drug order-entry systems to reduce future errors.
Researchers discovered that endothelial cells lack the transport protein used by tumours to eject foreign molecules, making them vulnerable to anti-cancer drug GSAO. This breakthrough could lead to more effective treatment strategies against various tumour types.
A new treatment approach using topotecan and carboplatin eliminates the need for etoposide, reducing the risk of leukemia. The study also suggests that vincristine contributes little to treating retinoblastoma, making it a promising alternative.
A recent study published in Nature Medicine reveals the importance of antigen-presenting cells in the graft-versus-leukemia effect, which occurs during bone marrow transplants. The discovery has significant implications for improving cellular immunotherapy and making it safer and more effective for cancer patients.
The new drug dnaJP1, derived from a naturally occurring protein dnaJ, has been found to be effective in treating rheumatoid arthritis by re-educating the immune system's tolerance to the amino acid sequence. In a double-blind trial, patients receiving dnaJP1 experienced lessening of symptoms and improvement in mobility.
The USC TREC Center will investigate how to prevent cancer by controlling obesity in children and adolescents, with a focus on high-risk ethnic groups.
Scientists found a gene named vav-1 that controls the timing of basic activities in nematode worms, including swallowing food, laying eggs, and defecating. The gene is related to human genes linked to cancer, suggesting it may be used to develop new treatments.
Researchers discovered that a specific gene variant can arise as a mutation during cancer development, contributing to tumor growth and spread. The study found the variant in nearly half of liver metastatic tumors, suggesting it may be an important target for new therapies.
Researchers found that NSAIDs reduced oral cancer risk by 53% in smokers and active users. However, long-term use of NSAIDs doubled the relative risk of death due to heart disease.
The new center aims to develop nanomaterials and nanodevices for cancer diagnostics, therapeutics, drug delivery, imaging, and monitoring applications. Researchers will focus on developing early detection tools, targeting cancer cells with chemotherapeutic agents, and creating new classes of drugs.
The School of Medicine will research and apply nanotechnology for the diagnosis and treatment of cancer. The nanotechnology offers several advantages, including precise targeting of tumor cells and drug therapies.
Gleevec has been found to reverse lung vascular remodeling and pulmonary hypertension in experimental models. Larger clinical trials are planned to test its safety and effectiveness.
Researchers at the University of Oxford discovered a family of amino acid transporters that promote cell growth when overexpressed in fruit flies, leading to excessive growth and tumour development. The findings suggest human equivalents of these genes may be involved in cancer, paving the way for potential new treatments.
Renal transplant recipients are 3.6 times more likely to develop melanoma than the general population, with a mortality rate up to 6 percent in some regions. Men who have had a kidney transplant face the greatest risk, and risk increases rapidly with age.
The NIH has renewed a network focused on understanding how genes influence drug responses, aiming to create personalized therapies with fewer side effects. The network will explore various genetic factors affecting medication efficacy and toxicity across nine NIH components.
Researchers found that farnesyl transferase inhibitors can normalize abnormal nuclei in progeria cells. The treatment targets a genetic mutation causing lamin A protein production issues.
A recent study has identified a molecular pathway linked to breast cancer recurrence, suggesting that the transcriptional repressor Snail may play a role in progression. Genetic screening of human breast cancer samples revealed that high levels of Snail expression predict decreased relapse-free survival.
Researchers have identified two ADAMTS genes, ADAMTS8 and ADAMTS15, that can help predict disease outcome in breast cancer patients. The study reveals four categories of risk based on gene activity levels, with those in the highest risk category three times more likely to experience recurrence.
Researchers found that the drug combination increased stem cell mobilization in 25 patients, reducing the number of necessary stem cell collections. This can lead to more successful transplantations and faster recovery for cancer patients.
A recent study confirms that letrozole treatment can improve the survival of women with node-positive disease and reduce metastasis risk. The study also found a 39% reduction in the risk of metastasis among participants receiving letrozole.
Researchers found that women taking letrozole experienced a significantly better overall disease-free survival rate and distant disease-free survival rate compared to those on placebo. This study confirms the protective effect of extended adjuvant letrozole therapy for postmenopausal breast cancer patients.
Researchers discover Chk1 protein plays natural defense against therapeutic damage in cancer cells, making treatment less effective. Combining chemotherapy agents with Chk1 inhibitors may increase efficacy and overcome clinical resistance.
A new study by Kishan Pandya and colleagues found that gabapentin significantly reduced hot flash severity scores in women with breast cancer. The results suggest that gabapentin can be added to the list of non-hormonal agents for controlling hot flashes in these patients, with further studies needed on higher doses.
A Stanford study found that combining vitamin D and nonsteroidal anti-inflammatory drugs (NSAIDs) suppresses prostate cancer growth more effectively than using either drug alone. The researchers discovered a 25-70% reduction in cell growth when calcitriol was used with NSAIDs, with potential implications for new treatment options.
Researchers develop stealth particles to deliver chemotherapy drugs to tumors, reducing phagocytosis by 24% in cell culture. The system allows for targeted delivery of lower doses, potentially improving cancer treatment outcomes.
Researchers identify six distinct p53 isoforms in human cells, revealing their potential role in modulating tumor suppressor activity and cell death. These findings may help identify patients at risk of developing aggressive cancer and inform personalized drug therapy.
Researchers at IRCM discover EAT-2 suppresses NK cell activity, boosting killer function to combat cancers and infections. Medications inhibiting EAT-2 may improve treatment effectiveness for cancers and communicable diseases.
The National Foundation for Cancer Research (NFCR) and the Prostate Cancer Foundation have partnered with the Burnham Institute to develop a 3D culture system that simulates tumor microenvironments. This technology enables rapid testing of candidate drugs and has potential applications beyond cancer research.
Researchers have found a way to get drugs past the blood-brain barrier to treat brain cancer. The compound JV-1-36, an antagonist of the hypothalamic growth hormone-releasing hormone, has shown promising results in treating malignant glioblastomas.
New study reveals that only about two-thirds of phase I clinical trial data were published within 7.5 years, highlighting the need for improvement in data dissemination. Lack of time and author relocation were cited as major obstacles to publication.
Researchers found that gefitinib was more effective at inhibiting cell growth and increasing apoptosis in NSCLC cells with mutant EGFR. In contrast, cetuximab showed no significant response in patients with EGFR mutations.
Researchers found that gefitinib (Iressa) was significantly effective in treating lung cancer cells containing a mutant EGFR molecule, while cetuximab (Erbitux) had little effect. The study suggests that mutations in the targets of designer drugs critically influence their effectiveness.
Researchers found that combining interferon with irinotecan boosts IRF5 protein levels in colon cancer cells, leading to increased cell death. The combination therapy may limit side effects and make it harder for cancer cells to build resistance.
Researchers have found that nearly 42% of ovarian cancer patient tumor tissues contain alterations in the protein km23. This discovery suggests km23 as a possible diagnostic indicator and therapeutic target for ovarian cancer. Further studies aim to develop a screening test and targeted therapies using km23.
A study published by Cedars-Sinai Medical Center has identified the EMP-1 protein as a biomarker for resistance to gefitinib, a targeted cancer drug used to treat non-small-cell lung cancer. The research found that EMP-1 is present in tumors of patients who fail to respond to treatment with gefitinib.
A team of UW-Madison scientists has developed a technique to easily manipulate and exchange the sugars found in chemicals produced in nature. This breakthrough could lead to the development of new anti-cancer treatments by allowing researchers to rapidly scan the roles of different sugars in complex natural products.
A study published in Developmental Cell reveals that connective tissue holding a cancer cell in place degrades, allowing it to spread to other parts of the body. The researchers identified a specific pathway critical for cancer cell activity, which could lead to more effective drug therapies with reduced side effects.
A new study has identified a protein called DOCK180 that senses chemicals inducing cell migration. This finding may lead to treatments halting cancer metastasis and immune disorders like arthritis and asthma by inhibiting inappropriate cell movement.
A recent study published in The Lancet found that a single dose of chemotherapy is comparable to radiotherapy in treating stage 1 seminoma. Patients who received chemotherapy had fewer seminomas occurring in their remaining testicle and were less likely to develop tumors.
A trial involving 731 patients found that treatment with erlotinib resulted in longer survival compared to a placebo, with patients on erlotinib surviving an average of 6.7 months versus 4.7 months. Erlotinib was also well-tolerated and improved physical function, quality of life, and symptoms.
Researchers identified a specific amino acid modification in Keap1 as the critical step that triggers increased Nrf2 and protective protein production, potentially leading to cancer prevention. The study's findings suggest that targeting this amino acid could lead to new cancer-fighting drugs.
Researchers have developed a novel inhibitor, SB-3CT, that protects against brain damage in mice undergoing a stroke. The treatment reduces brain damage to 30% and preserves neurological function, offering potential for new stroke treatments.
Researchers at USC discovered that anti-angiogenesis drugs increase glucose regulated protein 78 levels, blocking cell death and leading to drug resistance. Suppressing GRP78 gene expression can overcome resistance to chemotherapy drug etoposide.